Page 63 - MemoriaEHD-Eng

www.ciberehd.org

Most relevant • JuLià a, DoMèNeCh e, riCart e, tortosa r, garCía-sáNChez v, gisBert Jp. A genome-wide
association study on a southern European population identifies a new Crohn’s disea-
scientific
se susceptibility locus at RBX1-EP300.Gut. 2013 Oct;62(10):1440-5.
articles
• paNés J, López-saNroMáN a, BerMeJo F, garCía-sáNChez v, esteve M, torres y. Early azathio-
prine therapy is no more effective than placebo for newly diagnosed Crohn’s disease.

Gastroenterology. 2013 Oct;145(4):766-74.e1.

• CasaNova MJ, Chaparro M, DoMèNeCh e, Barreiro-De aCosta M, BerMeJo F, igLesias e. Safety
of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory

bowel disease.Am J Gastroenterol. 2013 Mar;108(3):433-40.

• Mañosa M, CaBré e, BerNaL i, esteve M, garCía-pLaNeLLa e, riCart e. Addition of metro-

nidazole to azathioprine for the prevention of postoperative recurrence of Crohn’s
disease: a randomized, double-blind, placebo-controlled trial.Inflamm Bowel Dis.

2013 Aug;19(9):1889-95.
é
• LoreNzo-zÚñiga v, Boix J, Mañosa M, LezCaNo C, CaBré e, MoreNo De vega v. Local injection
of infliximab in symptomatic isolated mucosal lesions: a novel scenario for endosco-

pic therapy?Inflamm Bowel Dis. 2013 Mar-Apr;19(4):E59-61.

The scientific activity of the inflammatory bowel disease (IBD) Unit of the Univer-
Highlights
sity Hospital and Institute “Germans Trias i Pujol” Foundation in 2013 has led to
obtain 20 international publications, ten of them in the 1st quartile in the area of

gastroenterology and hepatology. Of these, 3 belong to the first decile. Thus, the
accumulated impact factor was 79.968 in the last year.

Three collaborative studies CIBERehd have reached the first decile, showing: a)

the efficacy of thiopurines in moderate/severe flare-up in Crohn’s disease (CD)

(Pans, et al. Gastroenterol 2013); b) security of anti-TNF treatment during preg-
nancy (Casanova, et al. Am J Gastroenterol 2013); and c) a new CD susceptibility

locus identification between RBX1 and EP300 (Julià et al. GUT 2013). In the last

one, we contribute as corresponding author.

As in the case of the first quartile, the articles published in the second (3) and
third (3) quartil aim therapeutic improvement in IBD, in line with the objectives

established by CIBERehd. However, there have also been translational studies fun-
ded by governmental research programs in competitive submitting. In 2013, we

manage four active projects funded by the Carlos III Health Institute (FIS), which

allowed to get 58,086.05€ from public grants. In Addition, since two of them
have been renewed to 2014-2016 period (PI13/02198 and PI13/02217 ), the line

of research has gained more coherence and continuity. Other activities, such as

clinical trials (6 in 2013), courses and nonprofit donations have enabled to collect
56,630.50€ from private funds. Finally, it is interesting to remark educational and

formative activities such as the international course on IBD “Miquel Àngel Gassull”, 13
and a doctoral thesis on the role of intestinal axis IL10/p38MAPK in therapeutic 20
T
response in ulcerative colitis.
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

63